A TNF–JNK–Axl–ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma

[1]  S. Burma,et al.  Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma , 2016, Molecular Cancer Research.

[2]  M. Rudnicki,et al.  Control of glioblastoma tumorigenesis by feed-forward cytokine signaling , 2016, Nature Neuroscience.

[3]  K. Hatanpaa,et al.  Ligand-Independent EGFR Signaling. , 2015, Cancer research.

[4]  L. Recht,et al.  A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. , 2015, Neuro-oncology.

[5]  T. Cloughesy,et al.  Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma , 2015, Nature Reviews Cancer.

[6]  Sourav Bandyopadhyay,et al.  NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer. , 2015, Cell reports.

[7]  J. Donoghue,et al.  EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications , 2015, Oncogene.

[8]  S. Vandenberg,et al.  A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma. , 2015, Cancer research.

[9]  R. Abounader,et al.  Targeting MET for glioma therapy. , 2014, Neurosurgical focus.

[10]  T. Pandita,et al.  Constitutive and ligand-induced EGFR signaling triggers distinct and mutually exclusive downstream signaling networks , 2014, Nature Communications.

[11]  S. Kesari,et al.  An EGFR wild type–EGFRvIII–HB-EGF feed-forward loop regulates the activation of EGFRvIII , 2014, Oncogene.

[12]  Ho-June Lee,et al.  Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. , 2014, Cancer cell.

[13]  S. Pastorino,et al.  In silico modeling predicts drug sensitivity of patient-derived cancer cells , 2014, Journal of Translational Medicine.

[14]  K. Shah,et al.  Multiple lesions in receptor tyrosine kinase pathway determine glioblastoma response to pan-ERBB inhibitor PF-00299804 and PI3K/mTOR dual inhibitor PF-05212384 , 2014, Cancer biology & therapy.

[15]  J. Engelman,et al.  ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. , 2014, Cancer cell.

[16]  S. Nelson,et al.  Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA , 2014, Science.

[17]  P. Jänne,et al.  The quest to overcome resistance to EGFR-targeted therapies in cancer , 2013, Nature Medicine.

[18]  G. Reifenberger,et al.  EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. , 2013, Cancer cell.

[19]  S. Burma,et al.  Opposing effect of EGFRWT on EGFRvIII-mediated NF-κB activation with RIP1 as a cell death switch. , 2013, Cell reports.

[20]  Ivan Babic,et al.  De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. , 2013, Cancer discovery.

[21]  D. Shaw,et al.  Conformational Coupling across the Plasma Membrane in Activation of the EGF Receptor , 2013, Cell.

[22]  S. Hariono,et al.  Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers. , 2012, Cancer discovery.

[23]  Jian Jin,et al.  Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer , 2012, Cell.

[24]  R. Bernards,et al.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.

[25]  D. Housman,et al.  Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation. , 2011, Cancer research.

[26]  B. Halmos,et al.  MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents. , 2011, Cancer research.

[27]  S. Burma,et al.  Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance. , 2010, Neoplasia.

[28]  Yoshitaka Narita,et al.  Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. , 2010, Genes & development.

[29]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[30]  X. Gu,et al.  Intraperitoneal injection of thalidomide attenuates bone cancer pain and decreases spinal tumor necrosis factor-α expression in a mouse model , 2010, Molecular pain.

[31]  S. Toms,et al.  Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme , 2010, Journal of Neuro-Oncology.

[32]  Forest M White,et al.  Oncogenic EGFR Signaling Networks in Glioma , 2009, Science Signaling.

[33]  A. Unterberg,et al.  Therapeutic Inhibition of the Epidermal Growth Factor Receptor in High-Grade Gliomas: Where Do We Stand? , 2009, Molecular Cancer Research.

[34]  A. Scott,et al.  The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. , 2009, Neoplasia.

[35]  Caterina Giannini,et al.  Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  David E Levy,et al.  Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. , 2008, Genes & development.

[37]  Keith L. Ligon,et al.  Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies , 2007, Science.

[38]  H. Thaler,et al.  Inhibition of Jun NH2-Terminal Kinases Suppresses the Growth of Experimental Head and Neck Squamous Cell Carcinoma , 2007, Clinical Cancer Research.

[39]  Forest M White,et al.  Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma , 2007, Proceedings of the National Academy of Sciences.

[40]  Daniel A. Haber,et al.  Epidermal growth factor receptor mutations in lung cancer , 2007, Nature Reviews Cancer.

[41]  Susan M. Chang,et al.  A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme , 2007, Journal of Neuro-Oncology.

[42]  C. James,et al.  Use of an Orthotopic Xenograft Model for Assessing the Effect of Epidermal Growth Factor Receptor Amplification on Glioblastoma Radiation Response , 2006, Clinical Cancer Research.

[43]  Kimmo J Hatanpaa,et al.  Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells. , 2006, Cancer research.

[44]  Koji Yoshimoto,et al.  Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.

[45]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[46]  Allan H Friedman,et al.  Phase II trial of gefitinib in recurrent glioblastoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Liang Deng,et al.  Thalidomide inhibits tumor necrosis factor-alpha production and antigen presentation by Langerhans cells. , 2003, The Journal of investigative dermatology.

[48]  P. Scheurich,et al.  Tumor necrosis factor signaling , 2003, Cell Death and Differentiation.

[49]  B. Aggarwal,et al.  TNF induces internalization of the p60 receptor and shedding of the p80 receptor. , 1994, Journal of immunology.

[50]  P. Humphrey,et al.  Structural alterations of the epidermal growth factor receptor gene in human gliomas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.